All In Biotech

Free tool

FAERS Monitor: Adquey

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219474 or its brand name (Adquey, Difamilast). Reports on generic versions are filed under their own applications.

Reports

11

Serious

9

82% of reports

Hospitalization

4

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting2
  • blister1
  • chills1
  • cough1
  • cutaneous t-cell lymphoma1
  • dermatitis atopic1
  • eczema herpeticum1
  • eczema nummular1
  • erythema1
  • erythema multiforme1
  • feeding disorder1
  • metapneumovirus bronchitis1
  • no adverse event1
  • pigmentation disorder1
  • pruritus1

Reports by year received

View as table
YearReports
20251
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metapneumovirus bronchitis1957006.793427.9159,500
eczema herpeticum14142.9637.91,033
eczema nummular13922.2604.0978
cutaneous t-cell lymphoma11520.3234.4379
pigmentation disorder1309.747.876
erythema multiforme1205.031.650
feeding disorder194.314.523
dermatitis atopic136.35.68
blister134.05.38
chills116.32.53
no adverse event110.61.62
erythema19.31.41
vomiting28.12.37
cough16.81.11
pruritus15.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.